Denali Therapeutics Inc. (DNLI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ryan J. Watts Ph.D. | Co-Founder, President, CEO & Director | 1.15M | 3.65M | 1976 |
| Dr. Alexander O. Schuth M.D. | Co-Founder, CFO, COO & Secretary | 802.29k | 1.65M | 1973 |
| Dr. Marc Tessier-Lavigne Ph.D. | Co-Founder & Independent Director | 57.5k | -- | 1960 |
| Dr. Carole Ho M.D. | Chief Medical Officer & Head of Development | 802.29k | -- | 1973 |
| Mr. Tyler M. Nielsen | Senior Vice President of Corporate Finance | -- | -- | 1978 |
| Dr. Dana Andersen | Chief Technical and Manufacturing Officer | -- | -- | -- |
| Mr. Joe Lewcock Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Dr. Laura Hansen | Vice President of Investor Relations | -- | -- | -- |
| Mr. Chris Walsh | General Counsel | -- | -- | -- |
| Mr. Mark Rowen | Vice President of Corporate Development | -- | -- | -- |
Denali Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 445
Description
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Corporate Governance
Recent Events
- Apr 18, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Mar 22, 2024S-3ASR: Offering RegistrationsSee Full Filing
- Mar 01, 2024D: Additional FormsSee Full Filing
- Feb 28, 2024S-8: Offering RegistrationsSee Full Filing
- Feb 27, 20248-K: Corporate Changes & Voting MattersSee Full Filing